Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obatoclax +/- Rituximab in First-Line Follicular Lymphoma
NCT00427856Phase 2Completed
- Sponsor
- Gemin X Pharmaceuticals
- Start
- Mar 2007
- Primary completion
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of obatoclax in follicular lymphoma (FL) (2 arms), sponsored by Gemin X Pharmaceuticals. Primary endpoint: Response Rate at 12 weeks. Started Mar 2007; status: completed.
02
Drugs
obatoclax
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT00427856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00427856.